A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women with Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum
Principal Investigator
John Farley, MD
Status
Terminated
Date Opened To Accrual
April 01 2015
Date Closed to Accrual
October 31 2015
Date of Study Termination
February 09 2019
Disease Site
Gynecologic [GY]
Ovarian
Phase
II
Developmental Therapeutics
No
Primary Objective
To evaluate the anti-tumor activity of cabozantinib (XL184) in women with persistent or recurrent clear cell ovarian cancer, based on the proportion of patients who survive progression-free for at least 6 months and the proportion who have objective tumor response (complete or partial).
Patient Population
Patients must have recurrent or, progressive clear cell ovarian cancer not solely based on CA-125. Primary tumors must be at least 50% clear cell histomorphology in order to be eligible or have a histologically documented recurrence with at least 50% clear cell histomorphology.
Target Accrual
31
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.